Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13076665 | 0.91 | ADRB2 (0.52) | ADRB2ADRB1ADRB3C5AR1SLC2A1 | |
| SCHEMBL13697664 | 0.88 | ADRB2 (0.53) | ADRB2ADRB1ADRB3C5AR1 | |
| SCHEMBL14027864 | 0.86 | ADRB2 (0.56) | ADRB2ADRB1ADRB3FFAR1C5AR1 | |
| SCHEMBL13072322 | 0.86 | ADRB2 (0.54) | ADRB2ADRB1ADRB3FFAR1C5AR1 | |
| SCHEMBL21992018 | 0.85 | TP53 (0.49) | ADRB2ADRB1ADRB3TP53MAPT | |
| SCHEMBL21992419 | 0.84 | STK10 (0.51) | ADRB2ADRB1ADRB3TP53MAPT | |
| SCHEMBL13708439 | 0.78 | ADRB2 (0.51) | ADRB2ADRB1ADRB3FFAR1MAPT | |
| SCHEMBL9418464 | 0.77 | FFAR1 (0.45) | FFAR1SIGMAR1MAPT | |
| SCHEMBL14680607 | 0.77 | ALDH1A1 (0.47) | ADRB2ADRB1FFAR1SIGMAR1MAPT | |
| SCHEMBL5699638 | 0.77 | AGPAT2 (0.52) | ADRB2ADRB1ADRB3TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | GILEAD SCIENCES, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318396-A1 | CORTICOSTEROID LINKED BETA-AGONIST COMPOUNDS FOR USE IN THERAPY | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.